Gabelli Healthcare & WellnessRx Trust (GRX) director discloses insider share sales

Rhea-AI Filing Summary

Gabelli Healthcare & WellnessRx Trust director reports multiple share sales. A director of Gabelli Healthcare & WellnessRx Trust (ticker GRX) filed a Form 4 disclosing a series of open-market sales of common shares, par value $0.001, during August, September, and October 2025. Reported transactions include several sales of 2,000 shares and smaller blocks of 200 to 1,000 shares at prices around $9.1 to $9.5 per share. After these transactions, the reporting person directly beneficially owned 2,185 common shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

VANEKRIS ANTHONIE C

(Last) (First) (Middle)

ONE CORPORATE CENTER

(Street)

RYE NY 10580

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Gabelli Healthcare & WellnessRx Trust [ GRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares, Par Value $0.001	08/06/2025		S		2,000	D	$9.1198	9,185	D
Common Shares, Par Value $0.001	08/13/2025		S		2,000	D	$9.2	7,185	D
Common Shares, Par Value $0.001	09/04/2025		S		200	D	$9.5	6,985	D
Common Shares, Par Value $0.001	09/05/2025		S		800	D	$9.5	6,185	D
Common Shares, Par Value $0.001	10/08/2025		S		1,000	D	$9.2608	5,185	D
Common Shares, Par Value $0.001	10/09/2025		S		1,000	D	$9.27	4,185	D
Common Shares, Par Value $0.001	10/13/2025		S		1,000	D	$9.154	3,185	D
Common Shares, Par Value $0.001	10/14/2025		S		1,000	D	$9.122	2,185	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	John C. Ball as Attorney-in-Fact for Anthonie C. van Ekris	12/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does this Form 4 filing for GRX report?

The Form 4 reports that a director of Gabelli Healthcare & WellnessRx Trust (GRX) sold multiple blocks of common shares in open-market transactions and now directly owns 2,185 shares.

Who is the reporting person in the GRX Form 4?

The signature block identifies John C. Ball as Attorney-in-Fact for Anthonie C. van Ekris, indicating that Mr. van Ekris is the reporting person and a director of Gabelli Healthcare & WellnessRx Trust.

Over what period did the GRX director sell shares?

The reported sales of GRX common shares occurred between 08/06/2025 and 10/14/2025, covering several individual transaction dates within that time frame.

How many GRX shares were sold in the largest reported transactions?

The largest individual transactions reported in the Form 4 were sales of 2,000 common shares on multiple dates, including 08/06/2025 and 08/13/2025.

What prices were received for the GRX share sales?

The reported sale prices for GRX common shares ranged from about $9.1198 to $9.5 per share across the different transaction dates listed.

Does the GRX Form 4 show any derivative security transactions?

The section for derivative securities in the Form 4, such as options or warrants, does not list any acquisitions or dispositions of derivative securities for this reporting period.